Braga, Portugal

Centro Clinico Academico Braga

Idiopathic Thrombocytopenic Purpura

Antiphospholipid Syndrome

Bullous Pemphigoid

Dermatomyositis

Behcet Syndrome

Immune System Diseases

Syndrome

Thrombocytopenia

RAY121

Chugai Pharmaceutical

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Centro Clinico Academico Braga | Braga, Portugal

Site insights

Work at this site?

Active trials

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Trial sponsors